.png){kind=icon}
.png){kind=icon}
Return
Diosgenin inhibits necroptosis to alleviate NAFLD by blocking the RIPK1/RIPK3/MLKL pathway
.png){kind=icon}
PRE
AI
M
S
N
X
W
D
L
H
W
D
F
DOI：10.1016/j.jnutbio.2026.110449.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Diosgenin attenuated multipathological hallmarks of NAFLD across complementary experimental models. • DG protects against hepatic damage via blockade of necroptosis in vivo and in vitro. • We first propose that DG directly links RIPK1 targeting to RIPK3/MLKL execution. • DG can be a novel natural RIPK1 inhibitor to treat NAFLD effectively.
Keywords:
Diosgenin
TNF-RIPK1/3 pathway
NAFLD
Necroptosis
Natural product
Lipid accumulation
ALT
,
glutamic pyruvic transaminase
AST
,
glutamic oxaloacetic transaminase
DG
,
diosgenin
FFAs
,
free fatty acids
HDG
,
high-dose diosgenin
HFD
,
high-fat diet
LDG
,
low-dose diosgenin
LDH
,
lactate dehydrogenase
MLKL
,
mixed lineage kinase domain-like protein
NAFLD
,
nonalcoholic fatty liver disease
NASH
,
nonalcoholic steatohepatitis
Nec-1
,
necrostatin-1
RIPK1
,
receptor-interacting protein kinase-1
RIPK3
,
receptor-interacting protein kinase-3
ROS
,
reactive oxygen species
SIM
,
simvastatin
TC
,
total cholesterol
TG
,
triglycerides
TNF-α
,
tumor necrosis factor-α
TNFR1
,
tumor necrosis factor receptor-1
TRADD
,
tumor necrosis factor receptor-associated death domain protein
Journal
IF:
4.9
Papers:
4.5K
Citations:
1.4W
Organization
Cited Papers